... PALIVIZUMAB (Synagis™) helps to prevent or reduce the severity of infections caused by the respiratory syncytial virus (RSV). There are certain children who are especially at risk, and vaccination using this product helps reduce the chances that these infants and children will need hospital care. Palivizumab is an injection containing an antibody or protein that provides protection against RSV within a few days of use. The protection lasts for about 1 month. Palivizumab is given right before and during the months of the year that RSV infection is most likely to occur. ...
Drug Digest - more...

Resources